Background

Bruce Loveland is a cellular immunologist interested in the immune repertoire and how immune responses develop, are expressed and change. He has focused on studies of immune effector cells and the underlying genetic, molecular and physiological basis of immunity in organ transplantation, autoimmunity and viral immune responses. His career experience includes working at Melbourne University (PhD 1981), in London (MRC Clinical Research Centre, Harrow), Dallas (Howard Hughes Institute) and returning to Monash University, the Austin Research Institute (as NHMRC Senior Research Fellow, 1996-2004) and Burnet Institute.

Bruce has extensive experience in project and facilities management, cGLP and cGMP requirements, and in translational medical research with technical transfer from research laboratory to clinical trials, particularly for xenotransplantation and for cellular immunotherapies with Phase I and II clinical trials for cancer and persistent hepatitis C infection.

A major commitment with Associate Professor Rosemary Ffrench at Burnet Institute has been the establishment (2008) and expansion of the Burnet ImmunoMonitoring Facility Burnet (IMF), with quality management and deputy director roles. He is currently a Senior Fellow and Head, Research Support and Facilities at Burnet Institute.

Appointments

• 2015: Scientific Advisory Board, 360biolabs

Publications (89)

2020 (1)

• Testicular immune cell populations and macrophage polarisation in adult male mice and the influence of altered activin A levels.
  Indumathy S, Pueschl D, Klein B, Fietz D, Bergmann M, Schuppe HC, Da Silva N, Loveland BE, Hickey MJ, Hedger MP, Loveland KL
  J Reprod Immunol. 2020 Sep; 142:103204

2017 (2)

• Cytokines in male fertility and reproductive pathologies: immunoregulation and beyond.
  Loveland KL, Klein B, Pueschi D, Indumathy S, Bergmann M, Loveland BE, Hedger MP, Schuppe H
  Front Endocrin. 2017 Nov; 8:307
• An in vitro model demonstrates the potential of neoplastic human germ cells to influence the tumour microenvironment.
  Klein B, Schuppe HC, Bergmann M, Hedger MP, Loveland BE, Loveland KL
  Andrology. 2017 May; 5(4):763-770

2015 (1)

• Update on Mucin-1 immunotherapy in cancer: a clinical perspective.
  Rivalland G, Loveland B, Mitchell P
  Expert Opin Biol Ther. 2015 Oct; 15(12):1773-1787

2014 (1)

• A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.
  Mitchell PLR, Quinn MA, Grant PT, Allen DG, Jobling TW, White SC, Zhao A, Karanikas V, Vaughan H, Pietersz G, McKenzie IFC, Gargosky SE, Loveland BE
  J Immunother Can. 2014 May; 2:16

2013 (1)

• IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling.
  Li S, Lefranc MP, Miles JJ, Alamyar E, Giudicelli V, Duroux P, Freeman JD, Corbin VD, Scheerlinck JP, Frohman MA, Cameron PU, Plebanski M, Loveland B, Burrows SR, Papenfuss AT, Gowans EJ
  Nat Commun. 2013 Sep; 4:2333

2012 (1)

• Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals.
  Li S, Roberts S, Plebanski M, Gouillou M, Spelman T, Latour P, Jackson D, Brown L, Sparrow R, Prince M, Hart D, Loveland BE, Gowans EJ
  PLoS One. 2012 Aug; 7(8):e39368

2011 (2)

• Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survival.
  Li J, Loveland BE, Xing PX
  Cell Immunol. 2011 Sep; 272(1):87-93
• Dengue virus PrM/M proteins fail to show pH-dependent ion channel activity in Xenopus oocytes.
  Wong SS, Chebib M, Haqshenas G, Loveland B, Gowans EJ
  Virology. 2011 Mar; 412(1):83-90

2009 (4)

• Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets.
  van der Windt DJ, Bottino R, Casu A, Campanile N, Smetanka C, He J, Murase N, Hara H, Ball S, Loveland BE, Ayares D, Lakkis FG, Cooper DK, Trucco M
  Am J Transplant. 2009 Dec; 9(12):2716-2726
• Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.
  Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE, Aitken C, Barry S, Schofield L, Gowans EJ
  PLoS Pathog. 2009 Dec; 5(12):e1000707
• Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.
  Li J, Hu XF, Loveland BE, Xing PX
  Exp Hematol. 2009 Nov; 37(11):1284-1294
• The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity.
  van Spriel AB, Sofi M, Gartlan KH, van der Schaaf A, Verschueren I, Torensma R, Raymakers RA, Loveland BE, Netea MG, Adema GJ, Wright MD, Figdor CG
  PLoS Pathog. 2009 Mar; 5(3):e1000338

2008 (4)

• Cancer exploiting complement: a clue or an exception?
  Loveland BE, Cebon J
  Nat Immunol. 2008 Nov; 9(11):1205-1206
• Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors.
  Jones KL, Brown LE, Eriksson EMY, Ffrench RA, Latour PA, Loveland BE, Wall DM, Roberts SK, Jackson DC, Gowans EJ
  J Viral Hepat. 2008 Oct; 15(10):761-772
• In vivo tracking of dendritic cells in patients with multiple myeloma.
  H Miles Prince, Dominic M Wall, David Ritchie, Dirk Honemann, Simon Harrrison, Hang Quach, Mick Thompson, Rodney Hicks, Eddie Lau, Jill Davison, Maureen Loudovaris, Jude Moloney, Bruce Loveland, Jacques Bartholeyns, Andrew Katsifis, Linda Mileshkin
  J Immunother. 2008 Feb; 31(2):166-179
• Vaccination with in vitro grown whole tumor cells induces strong immune responses and retards tumor growth in a murine model of colorectal liver metastases.
  Fifis T, Lam I, Lin D, Malcontenti-Wilson C, Christophi C, Loveland B
  Vaccine. 2008 Jan; 26(2):241-249

2007 (1)

• Dendritic cell vaccination.
  Proudfoot O, Pouniotis D, Sheng KC, Loveland BE, Pietersz GA
  Expert Rev Vaccines. 2007 Aug; 6(4):617-633

2006 (3)

• Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
  Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S
  Breast Cancer Res. 2006 Jun; 8(3):R27
• Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses.
  Apostolopoulos V, Pouniotis DS, van Maanen PJ, Andriessen RW, Lodding J, Xing PX, McKenzie IF, Loveland BE, Pietersz GA
  Vaccine. 2006 Apr; 24(16):3191-3202
• Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
  Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL
  Clin Cancer Res. 2006 Feb; 12(3 Pt 1):869-877

2004 (2)

• Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
  Newcombe NG, Beagley LG, Christiansen D, Loveland BE, Johansson ES, Beagley KW, Barry RD, Shafren DR
  J Virol. 2004 Nov; 78(22):12677-12682
• Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
  Loveland BE, Milland J, Kyriakou P, Thorley BR, Christiansen D, Lanteri MB, Regensburg M, Duffield M, French AJ, Williams L, Baker L, Brandon MR, Xing PX, Kahn D, McKenzie IF
  Xenotransplantation. 2004 Mar; 11(2):171-183

2003 (3)

• Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis.
  Crimeen-Irwin B, Ellis S, Christiansen D, Ludford-Menting MJ, Milland J, Lanteri M, Loveland BE, Gerlier D, Russell SM
  J Biol Chem. 2003 Nov; 278(47):46927-46937
• CD46 protects pig islets from antibody but not cell-mediated destruction in the mouse.
  McKenzie IF, Li YQ, Xing PX, Dinatale I, Koulmanda M, Loveland BE, Sandrin MS
  Xenotransplantation. 2003 Nov; 10(6):615-621
• Aspects of cancer immunotherapy.
  McKenzie IF, Apostolopoulos V, Plebanski M, Pietersz GA, Loveland BE
  Immunol Cell Biol. 2003 Feb; 81(1):79-85

2002 (3)

• Identification of the streptococcal M protein binding site on membrane cofactor protein (CD46).
  Giannakis E, Jokiranta TS, Ormsby RJ, Duthy TG, Male DA, Christiansen D, Fischetti VA, Bagley C, Loveland BE, Gordon DL
  J Immunol. 2002 May; 168(9):4585-4592
• A CD46CD[55-46] chimeric receptor, eight short consensus repeats long, acts as an inhibitor of both CD46 (MCP)- and CD150 (SLAM)-mediated cell-cell fusion induced by CD46-using measles virus.
  Christiansen D, De Sousa ER, Loveland B, Kyriakou P, Lanteri M, Wild FT, Gerlier D
  J Gen Virol. 2002 May; 83(Pt 5):1147-1155
• A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization.
  Ludford-Menting MJ, Thomas SJ, Crimeen B, Harris LJ, Loveland BE, Bills M, Ellis S, Russell SM
  J Biol Chem. 2002 Feb; 277(6):4477-4484

2001 (2)

• Genetic engineering for xenotransplantation.
  Sandrin MS, Loveland BE, IMcKenzie IF
  J Card Surg. 2001 Nov; 16(6):448-457
• Mechanism of measles virus-induced suppression of inflammatory immune responses.
  Marie JC, Kehren J, Trescol-Biémont MC, Evlashev A, Valentin H, Walzer T, Tedone R, Loveland B, Nicolas JF, Rabourdin-Combe C, Horvat B
  Immunity. 2001 Jan; 14(1):69-79

2000 (5)

• A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
  Spendlove L, Li L, Potter V, Christiansen D, Loveland BE, Durrant LG
  Eur J Immunol. 2000 Oct; 30(10):2944-2953
• Are pigs transgenic for human complement regulatory proteins necessary for xenotransplantation?
  Loveland BE, Cooper DK, Sandrin MS
  Transplantation. 2000 Aug; 70(4):567-568
• Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
  Christiansen D, Loveland B, Kyriakou P, Lanteri M, Rubinstein E, Gerlier D
  Mol Immunol. 2000 Aug; 37(12-13):687-696
• Interaction of CD46 with measles virus: accessory role of CD46 short consensus repeat IV.
  Christiansen D, Loveland B, Kyriakou P, Lanteri M, Escoffier C, Gerlier D
  J Gen Virol. 2000 Apr; 81(Pt 4):911-917
• Inhibition of hyperacute transplant rejection by soluble proteins with the functional domains of CD46 and FcgammaRII.
  Lanteri MB, Powell MS, Christiansen D, Li YQ, Hogarth PM, Sandrin MS, Mckenzie IF, Loveland BE
  Transplantation. 2000 Mar; 69(6):1128-1136

1999 (1)

• Autoreactive cytotoxic T cells in mice are induced by immunization with a conserved mitochondrial enzyme in Freund's complete adjuvant.
  Karanikas V, Rowley MJ, MacKay IR, Loveland BE
  Immunology. 1999 Jun; 97(2):264-271

1998 (1)

• Current and future prospects for xenotransplantation.
  French AJ, Greenstein JL, Loveland BE, Mountford PS
  Reprod Fertil Dev. 1998 Jan; 10(7-8):683-696

1997 (1)

• Transgenic expression of a CD46 (membrane cofactor protein) minigene: studies of xenotransplantation and measles virus infection.
  Thorley BR, Milland J, Christiansen D, Lanteri MB, McInnes B, Moeller I, Rivailler P, Horvat B, Rabourdin-Combe C, Gerlier D, McKenzie IF, Loveland BE
  Eur J Immunol. 1997 Mar; 27(3):726-734

1996 (3)

• Interactions between the ectodomains of haemagglutinin and CD46 as a primary step in measles virus entry.
  Devaux P, Loveland B, Christiansen D, Milland J, Gerlier D
  J Gen Virol. 1996 Jul; 77 ( Pt 7):1477-1481
• A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro.
  Christiansen D, Milland J, Thorley BR, McKenzie IF, Loveland BE
  Eur J Immunol. 1996 Mar; 26(3):578-585
• Engineering of recombinant soluble CD46: an inhibitor of complement activation.
  Christiansen D, Milland J, Thorley BR, McKenzie IF, Mottram PL, Purcell LJ, Loveland BE
  Immunology. 1996 Mar; 87(3):348-354

1995 (4)

• CTL in mice immunized with human mucin 1 are MHC-restricted.
  Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF
  J Immunol. 1995 Dec; 155(11):5089-5094
• Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.
  Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF
  Proc Natl Acad Sci U S A. 1995 Oct; 92(22):10128-10132
• Hepatic portal infiltrates in mice immunized with syngeneic lymphoid cells: connotations for models of autoimmune liver disease.
  Karanikas V, MacKay IR, Rowley MJ, Veitch B, Loveland BE
  J Gastroenterol Hepatol. 1995 Sep; 10(5):491-497
• Construction of CD46 minigenes for the production of transgenic mice.
  Thorley BR, McInnes B, Christiansen D, McKenzie IF, Loveland BE
  Transplant Proc. 1995 Jun; 27(3):2177-2178

1994 (5)

• Gal alpha(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies.
  Vaughan HA, Loveland BE, Sandrin MS
  Transplantation. 1994 Oct; 58(8):879-882
• Measles virus receptor properties are shared by several CD46 isoforms differing in extracellular regions and cytoplasmic tails.
  Gerlier D, Loveland B, Varior-Krishnan G, Thorley B, McKenzie IF, Rabourdin-Combe C
  J Gen Virol. 1994 Sep; 75 ( Pt 9):2163-2171
• Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59.
  Loveland BE, Szokolai K, Johnstone RW, McKenzie IF
  Transplant Proc. 1994 Jun; 26(3):1070-1071
• Tissue-specific expression of CD46 protein isoforms due to production of RNA splice variants.
  Johnstone RW, Russell S, Loveland BE, McKenzie IF
  Transplant Proc. 1994 Jun; 26(3):1248
• Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease.
  Davies ME, Horner A, Loveland BE, McKenzie IF
  Scand J Rheumatol. 1994 Jan; 23(6):316-321

1993 (7)

• Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing.
  Johnstone RW, Russell SM, Loveland BE, McKenzie IF
  Mol Immunol. 1993 Oct; 30(14):1231-1241
• Antisense oligonucleotides decrease expression of human CD46, a regulator of complement.
  Milland J, Loveland BE, Russell SM, McKenzie IF
  Transplant Proc. 1993 Oct; 25(5):2922-2923
• Identification and quantification of complement regulator CD46 on normal human tissues.
  Johnstone RW, Loveland BE, McKenzie IF
  Immunology. 1993 Jul; 79(3):341-347
• Autoreactive MHC-restricted cytotoxic cells in BALB/c mice after novel immunisation with a conserved mammalian autoantigen.
  V Karanikas, I R Mackay, M J Rowley, B E Loveland
  Cell Immunol. 1993 Apr; 148(1):166-176
• CD46 (MCP) confers protection from lysis by xenogeneic antibodies.
  Loveland BE, Johnstone RW, Russell SM, Thorley BR, McKenzie IF
  Transplant Proc. 1993 Feb; 25(1 Pt 1):396-397
• Isolation of a clone for pig beta 2-microglobulin cDNA.
  Milland J, Loveland BE, McKenzie IF
  Immunogenetics. 1993 Jan; 38(6):464
• Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis.
  B E Loveland, R W Johnstone, S M Russell, B R Thorley, I F McKenzie
  Transpl Immunol. 1993 Jan; 1(2):101-108

1992 (6)

• Differing epitope selection of experimentally-induced and natural antibodies to a disease-specific autoantigen, the E2 subunit of pyruvate dehydrogenase complex (PDC-E2).
  M J Rowley, T Maeda, I R Mackay, B E Loveland, G L McMullen, G Tribbick, C C Bernard
  Int Immunol. 1992 Nov; 4(11):1245-1253
• Functional characterisation of alternatively spliced CD46 cytoplasmic tails.
  Russell SM, Loveland BE, Johnstone RW, Thorley BR, McKenzie IF
  Transplant Proc. 1992 Oct; 24(5):2329-2330
• Tissue-specific expression of CD46 isoforms.
  Johnstone RW, Russell SM, Loveland BE, Jayasuriya N, McKenzie I F
  Transplant Proc. 1992 Oct; 24(5):2331-2332
• Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays.
  B E Loveland, T G Johns, I R Mackay, F Vaillant, Z X Wang, P J Hertzog
  Biochem Int. 1992 Jul; 27(3):501-510
• The molecular basis of CD46 polymorphic expression and demonstration of a protective role against lysis by xenosera.
  Loveland B, Russell S, Purcell D, Johnstone R, Thorley B, Sparrow R, McKenzie I
  Transplant Proc. 1992 Apr; 24(2):685-686
• T-cell tolerance induced in nude mice grafted with thymic epithelium.
  J H Robinson, C J Chapman, B E Loveland, R K Jordan
  Immunology. 1992 Feb; 75(2):318-324

1991 (6)

• Autoantibody against dihydrolipoamide dehydrogenase, the E3 subunit of the 2-oxoacid dehydrogenase complexes: significance for primary biliary cirrhosis.
  T Maeda, B E Loveland, M J Rowley, I R Mackay
  Hepatology. 1991 Dec; 14(6):994-999
• Characterization of the spontaneous mutant H-2Kbm29 indicates that gene conversion in H-2 occurs at a higher frequency than detected by skin grafting.
  R M Horton, B E Loveland, A Parwani, L R Pease, K F Lindahl
  J Immunol. 1991 Nov; 147(9):3180-3184
• H-2M3 encodes the MHC class I molecule presenting the maternally transmitted antigen of the mouse.
  C R Wang, B E Loveland, K F Lindahl
  Cell. 1991 Jul; 66(2):335-345
• Cellular location of thymus-leukemia (TL) antigen as shown by immuno-cryoultramicrotomy.
  C Hartfield, A McDowall, B Loveland, K Fischer Lindahl
  J Electron Microsc Tech. 1991 Jun; 18(2):148-156
• Maternally transmitted antigen of mice: a model transplantation antigen.
  K Fischer Lindahl, E Hermel, B E Loveland, C R Wang
  Annu Rev Immunol. 1991 Apr; 9:351-372
• Some biochemical properties of human lymphoblastoid Namalwa cells grown anaerobically.
  F Vaillant, B E Loveland, P Nagley, A W Linnane
  Biochem Int. 1991 Feb; 23(3):571-580

1990 (2)

• IgG antibody and delayed-type hypersensitivity responses in nude mice grafted with thymic epithelium.
  R K Jordan, C J Chapman, S M McLachlan, D Milne, B E Loveland, J H Robinson
  Immunology. 1990 Aug; 70(4):453-457
• Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein.
  B Loveland, C R Wang, H Yonekawa, E Hermel, K F Lindahl
  Cell. 1990 Mar; 60(6):971-980

1988 (1)

• MHC-unrestricted T-cell cytotoxicity against tumour cells.
  A M Sponaas, B Loveland, E Simpson
  Immunology. 1988 Feb; 63(2):233-239

1987 (3)

• Lymphokine-activated killer cell activity in rheumatoid arthritis.
  M Jira, M Malkovsky, A M Denman, B Loveland, D Lyons, A G Dalgleish, A D Webster
  Clin Exp Immunol. 1987 Jun; 68(3):535-542
• Generation of lymphokine-activated killer cells does not require DNA synthesis.
  M Malkovsky, M Jira, J Madar, V Malkovska, B Loveland, G L Asherson
  Immunology. 1987 Mar; 60(3):471-473
• Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.
  M Malkovsky, B Loveland, M North, G L Asherson, L Gao, P Ward, W Fiers
  Nature. 1987 Jan; 325(6101):262-265

1986 (3)

• Autologous lymphoid cells exposed to recombinant interleukin-2 in vitro in the absence of antigen can induce the rejection of long-term tolerated skin allografts.
  B Loveland, R Hunt, M Malkovsky
  Immunology. 1986 Sep; 59(1):159-161
• Reduced expression of interleukin-2 receptors in hypogammaglobulinaemia: a possible cause of higher cancer incidence.
  M Malkovsky, M Jira, L Gao, B Loveland, V Malkovska, A G Dalgleish, A D Webster
  Lancet. 1986 Jun; 1(8495):1442-1443
• T-cell and antibody typing of a mouse population segregating for Sxr and H-2 haplotype.
  E Simpson, P Chandler, K Tomonari, B Loveland, A McLaren
  Cell Immunol. 1986 Mar; 98(1):46-56

1985 (2)

• The failure of female cells to present in vitro the male H-Y antigen for secondary cytotoxic T-cell responses.
  G Biasi, F Dazzi, B Loveland, R Rivarollo, G Asherson
  Immunogenetics. 1985 Jan; 22(2):177-181
• Mapping H-1 with the distal break point of chromosome 7 in Cattanach's insertion.
  B E Loveland, A M Sponaas, E Simpson
  Immunogenetics. 1985 Jan; 22(5):503-510

1982 (5)

• Delayed-type hypersensitivity and allograft rejection in the mouse: correlation of effector cell phenotype.
  B E Loveland, I F McKenzie
  Immunology. 1982 Jun; 46(2):313-320
• Cells mediating graft rejection in the mouse. IV. The Ly-5, 6, and 8 effector cell phenotype.
  B E Loveland, I F McKenzie
  Transplantation. 1982 Apr; 33(4):411-413
• Cells mediating graft rejection in the mouse. III. Ly-1+ precursor T cells generate skin graft rejection.
  B E Loveland, I F McKenzie
  Transplantation. 1982 Apr; 33(4):407-410
• Which T cells cause graft rejection?
  B E Loveland, I F McKenzie
  Transplantation. 1982 Mar; 33(3):217-221
• Cells mediating graft rejection in the mouse. II. The Ly phenotypes of cells producing tumor allograft rejection.
  B E Loveland, I F McKenzie
  Transplantation. 1982 Feb; 33(2):174-180

1981 (3)

• Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection.
  B E Loveland, P M Hogarth, R Ceredig, I F McKenzie
  J Exp Med. 1981 May; 153(5):1044-1057
• The key role of Lyt-1+ cells in skin graft rejection in the mouse.
  B Loveland, R Ceredig, M Hogarth, I McKenzie
  Transplant Proc. 1981 Mar; 13(1 Pt 2):1079-1081
• The detection of beta-adrenoceptors on murine lymphocytes.
  B E Loveland, B Jarrott, I F McKenzie
  Int J Immunopharmacol. 1981 Jan; 3(1):45-55

News Articles (5)

2017 (1)

• New first for Burnet in biosafety

2015 (1)

• Cancer Appeal needs your support

2014 (1)

• Behind the Microscope Discovery Tour a great hit!

2012 (1)

• New hepatitis C vaccine offers hope

2011 (1)

• Burnet staff and donors recognised at Excellence Awards